<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574336</url>
  </required_header>
  <id_info>
    <org_study_id>SHAFT</org_study_id>
    <nct_id>NCT04574336</nct_id>
  </id_info>
  <brief_title>Scandinavian Humeral Diaphyseal Fracture Trial</brief_title>
  <acronym>SHAFT</acronym>
  <official_title>Scandinavian Humeral diAphyseal Fracture Trial - A Pragmatic Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kolding Sygehus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Slagelse Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aabenraa Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sydvestjysk Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kolding Sygehus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study includes adult participants with a humeral shaft fracture. The study is divided&#xD;
      into two large RCTs which will differ in age cut-off and time interval for cross-over from&#xD;
      non-surgical to surgical treatment. The trials will include 100 participants each and be&#xD;
      conducted in hospitals around Denmark, Sweden and Norway.&#xD;
&#xD;
      The hypothesis is that primary surgical treatment results in less symptoms and better&#xD;
      function than non-surgical treatment with the option of early identification and treatment&#xD;
      cross-over of failed treatment. Participants will be randomized 1:1 between non-surgical&#xD;
      treatment and surgical treatment. The specific procedure is decided by treating&#xD;
      surgeon/hospital. The primary outcome is the DASH-score after 52 weeks. The secondary&#xD;
      outcomes include: DASH-score at 26 weeks, EQ-5D-5L, complications, pain, fracture site&#xD;
      mobility, return to work and willingness to repeat treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to compare surgical fixation of humeral shaft fracture to non-surgical&#xD;
      treatment with early identification and treatment of failed treatment.&#xD;
&#xD;
      The trial is divided into two separate RCT's:&#xD;
&#xD;
        1. SHAFT-Y for the young with an age cut-off of 18 to 64 years. The early identification&#xD;
           and treatment of delayed union is set to 6 to 12 weeks&#xD;
&#xD;
        2. SHAFT-E for the elder with an age cut-off +65 years. The early identification and&#xD;
           treatment of delayed union is set to 12 to 26 weeks&#xD;
&#xD;
      The trials are otherwise identical and the primary outcome is the DASH-score at 52 weeks&#xD;
      after primary intervention. The SHAFT trial is divided into two trials as there is a bimodial&#xD;
      age distribution with more elderly than young thereby possibly skewing the results if the age&#xD;
      groups where combined.&#xD;
&#xD;
      The SHAFT trial will be conducted in hospitals around Denmark, Sweden and Norway.&#xD;
&#xD;
      Patients admitted to the emergency department in one of the trial sites and fulfil the&#xD;
      eligibility criterias, will be invited to enroll into the trial. They will be given time to&#xD;
      consider and be scheduled for a consultation with a trial worker (non-physician) within 7&#xD;
      days. Written consent will be obtained at the consultation and randomization will occur&#xD;
      immediately after. If patients do not wish to enroll to the RCT, they will be asked to&#xD;
      consider enrollment in an observational cohort.&#xD;
&#xD;
      Treatment will be performed within 14 days after injury&#xD;
&#xD;
        -  Surgical treatment. The specific treatment is decided by the treating surgeon/department&#xD;
&#xD;
        -  Non-surgical treatment with the option of early secondary surgery from 6-12 weeks for&#xD;
           SHAFT-Y and 12-26 weeks for SHAFT-E&#xD;
&#xD;
      Participants will be assigned to the trial with an allocation of 1:1 to either surgical&#xD;
      treatment or non-surgical treatment. The trial worker (non-physician) acquires the allocated&#xD;
      treatment from REDCap and initiates the treatment, either by scheduling the surgery date or&#xD;
      applying the chosen non-surgical method.&#xD;
&#xD;
      The total sample size is estimated to 100 participants in each trial and is powered to detect&#xD;
      a minimal important change (MIC) of 7 points in DASH. The standard deviation(SD) is ±10. The&#xD;
      investigators used an α-level of 0.05 and β-level of 0.10. The primary sample size&#xD;
      calculation is based on these assumptions and a total of 43 participants are required per&#xD;
      group. The allowance of attrition is set to 15%.&#xD;
&#xD;
      Participants will be included consecutively to an observational group until the sample size&#xD;
      for the RCT is completed. The trial management committee can decide to pool data from both&#xD;
      RCTs (SHAFT-E, SHAFT-Y) if recruitment is prolonged.&#xD;
&#xD;
      Statistical analysis for the study will be performed by an blinded independent statistician.&#xD;
&#xD;
      Follow-ups are planned at 2 weeks, 6 weeks, 12 weeks, 26 weeks and 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DASH-score</measure>
    <time_frame>52 weeks</time_frame>
    <description>A patient-reported outcome measure specific for physical function and symptoms of the upper limb (Disability of Arm, Shoulder and Hand-DASH)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 26 weeks, 52 weeks</time_frame>
    <description>EuroQol questionnaire for patient reported outcome concerning health related quality of life measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks, 12 weeks, 26 weeks, 52 weeks</time_frame>
    <description>Complications related to the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS-score</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks, 12 weeks, 26 weeks, 52 weeks</time_frame>
    <description>Pain score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fracture site mobility</measure>
    <time_frame>2 weeks, 6 weeks, 12 weeks, 26 weeks, 52 weeks</time_frame>
    <description>Gross motor instability test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to work</measure>
    <time_frame>6 weeks, 12 weeks, 26 weeks, 52 weeks</time_frame>
    <description>Time from fracture to return to work</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Willingness to repeat treatment</measure>
    <time_frame>52 weeks</time_frame>
    <description>Anchor question</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fracture Humerus of Shaft</condition>
  <arm_group>
    <arm_group_label>Surgical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary surgery of humeral shaft fracture with surgeons choice of osteosynthesis method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-surgical treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of humeral shaft fracture with sling and/or functional brace</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical treatment</intervention_name>
    <description>We anticipate that surgical treatment will include plate osteosynthesis (MIPO and ORIF), intramedullary nailing (antegrade and retrograde) and external fixation. Plate and nail types, screw configuration and surgical approaches will be decided by the surgeon. The procedure will be conducted or supervised by a senior consultant.</description>
    <arm_group_label>Surgical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Non-surgical treatment</intervention_name>
    <description>Non-surgical treatment will include sugar tong, splint, plaster splints, hanging casts, or functional bracing as the Sarmiento brace and will be worn until a surgeon removes it. If the surgeon deems it appropriate, participants will be offered to undergo early secondary surgery with a surgical procedure of their choice. The participants will be recorded and the reason will be noted. We anticipate the surgical procedures will be similar to the previous mentioned and perhaps with the addition of bone graft.</description>
    <arm_group_label>Non-surgical treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Fracture types 12A-C (OTA/AO classification)&#xD;
&#xD;
          2. Treatment within 14 days from trauma&#xD;
&#xD;
          3. Age 18-64 years for SHAFT-Y and +65 years for SHAFT-E&#xD;
&#xD;
          4. Participants must understand the information given and be able to read and speak&#xD;
             Danish, Swedish or Norwegian to complete the study paperwork&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to give informed consent&#xD;
&#xD;
          2. Undisplaced shaft fracture (less than a cortex-wide displacement in one radiographic&#xD;
             plane)&#xD;
&#xD;
          3. Displaced fractures of the proximal and distal humeral (more than a cortex-wide&#xD;
             displacement in one radiographic plane)&#xD;
&#xD;
          4. Vascular injury in ipsilateral arm&#xD;
&#xD;
          5. Polytrauma&#xD;
&#xD;
          6. Pathological fracture&#xD;
&#xD;
          7. Open fracture&#xD;
&#xD;
          8. Floating shoulder fractures&#xD;
&#xD;
          9. Floating elbow fractures&#xD;
&#xD;
         10. BMI &gt; 40&#xD;
&#xD;
         11. Health conditions preventing treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bjarke Viberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Lillebaelt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dennis Karimi, M.D</last_name>
    <phone>28971003</phone>
    <email>denniskarimi@gmail.com</email>
  </overall_contact>
  <reference>
    <citation>Kim SH, Szabo RM, Marder RA. Epidemiology of humerus fractures in the United States: nationwide emergency department sample, 2008. Arthritis Care Res (Hoboken). 2012 Mar;64(3):407-14. doi: 10.1002/acr.21563.</citation>
    <PMID>22162357</PMID>
  </reference>
  <reference>
    <citation>Ekholm R, Adami J, Tidermark J, Hansson K, Törnkvist H, Ponzer S. Fractures of the shaft of the humerus. An epidemiological study of 401 fractures. J Bone Joint Surg Br. 2006 Nov;88(11):1469-73.</citation>
    <PMID>17075092</PMID>
  </reference>
  <reference>
    <citation>Gosler MW, Testroote M, Morrenhof JW, Janzing HM. Surgical versus non-surgical interventions for treating humeral shaft fractures in adults. Cochrane Database Syst Rev. 2012 Jan 18;1:CD008832. doi: 10.1002/14651858.CD008832.pub2. Review.</citation>
    <PMID>22258990</PMID>
  </reference>
  <reference>
    <citation>Harkin FE, Large RJ. Humeral shaft fractures: union outcomes in a large cohort. J Shoulder Elbow Surg. 2017 Nov;26(11):1881-1888. doi: 10.1016/j.jse.2017.07.001.</citation>
    <PMID>29054684</PMID>
  </reference>
  <reference>
    <citation>Matsunaga FT, Tamaoki MJ, Matsumoto MH, Netto NA, Faloppa F, Belloti JC. Minimally Invasive Osteosynthesis with a Bridge Plate Versus a Functional Brace for Humeral Shaft Fractures: A Randomized Controlled Trial. J Bone Joint Surg Am. 2017 Apr 5;99(7):583-592. doi: 10.2106/JBJS.16.00628.</citation>
    <PMID>28375891</PMID>
  </reference>
  <reference>
    <citation>van Middendorp JJ, Kazacsay F, Lichtenhahn P, Renner N, Babst R, Melcher G. Outcomes following operative and non-operative management of humeral midshaft fractures: a prospective, observational cohort study of 47 patients. Eur J Trauma Emerg Surg. 2011 Jun;37(3):287-96. doi: 10.1007/s00068-011-0099-0. Epub 2011 Apr 1.</citation>
    <PMID>21837261</PMID>
  </reference>
  <reference>
    <citation>Gottschalk MB, Carpenter W, Hiza E, Reisman W, Roberson J. Humeral Shaft Fracture Fixation: Incidence Rates and Complications as Reported by American Board of Orthopaedic Surgery Part II Candidates. J Bone Joint Surg Am. 2016 Sep 7;98(17):e71. doi: 10.2106/JBJS.15.01049. Review. Erratum in: J Bone Joint Surg Am. 2021 Mar 3;103(5):e21.</citation>
    <PMID>27605696</PMID>
  </reference>
  <reference>
    <citation>Rämö L, Sumrein BO, Lepola V, Lähdeoja T, Ranstam J, Paavola M, Järvinen T, Taimela S; FISH Investigators. Effect of Surgery vs Functional Bracing on Functional Outcome Among Patients With Closed Displaced Humeral Shaft Fractures: The FISH Randomized Clinical Trial. JAMA. 2020 May 12;323(18):1792-1801. doi: 10.1001/jama.2020.3182.</citation>
    <PMID>32396179</PMID>
  </reference>
  <reference>
    <citation>Hosseini Khameneh SM, Abbasian M, Abrishamkarzadeh H, Bagheri S, Abdollahimajd F, Safdari F, Rahimi-Dehgolan S. Humeral shaft fracture: a randomized controlled trial of nonoperative versus operative management (plate fixation). Orthop Res Rev. 2019 Sep 23;11:141-147. doi: 10.2147/ORR.S212998. eCollection 2019.</citation>
    <PMID>31576178</PMID>
  </reference>
  <reference>
    <citation>Oliver WM, Carter TH, Graham C, White TO, Clement ND, Duckworth AD, Molyneux SG. A prospective randomised controlled trial of operative versus non-operative management of fractures of the humeral diaphysis: the HUmeral Shaft Fracture FIXation (HU-FIX) Study protocol. Trials. 2019 Aug 5;20(1):475. doi: 10.1186/s13063-019-3576-0.</citation>
    <PMID>31383027</PMID>
  </reference>
  <reference>
    <citation>Kurup H, Hossain M, Andrew JG. Dynamic compression plating versus locked intramedullary nailing for humeral shaft fractures in adults. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD005959. doi: 10.1002/14651858.CD005959.pub2. Review.</citation>
    <PMID>21678350</PMID>
  </reference>
  <reference>
    <citation>Driesman AS, Fisher N, Karia R, Konda S, Egol KA. Fracture Site Mobility at 6 Weeks After Humeral Shaft Fracture Predicts Nonunion Without Surgery. J Orthop Trauma. 2017 Dec;31(12):657-662. doi: 10.1097/BOT.0000000000000960.</citation>
    <PMID>28708781</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.</citation>
    <PMID>23303884</PMID>
  </reference>
  <reference>
    <citation>Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ. 2015 May 8;350:h2147. doi: 10.1136/bmj.h2147.</citation>
    <PMID>25956159</PMID>
  </reference>
  <reference>
    <citation>Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr;42(2):377-81. doi: 10.1016/j.jbi.2008.08.010. Epub 2008 Sep 30.</citation>
    <PMID>18929686</PMID>
  </reference>
  <reference>
    <citation>Hudak PL, Amadio PC, Bombardier C. Development of an upper extremity outcome measure: the DASH (disabilities of the arm, shoulder and hand) [corrected]. The Upper Extremity Collaborative Group (UECG). Am J Ind Med. 1996 Jun;29(6):602-8. Erratum in: Am J Ind Med 1996 Sep;30(3):372.</citation>
    <PMID>8773720</PMID>
  </reference>
  <reference>
    <citation>EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208.</citation>
    <PMID>10109801</PMID>
  </reference>
  <reference>
    <citation>Kunutsor SK, Barrett MC, Whitehouse MR, Blom AW. Venous thromboembolism following 672,495 primary total shoulder and elbow replacements: Meta-analyses of incidence, temporal trends and potential risk factors. Thromb Res. 2020 May;189:13-23. doi: 10.1016/j.thromres.2020.02.018. Epub 2020 Feb 20.</citation>
    <PMID>32135385</PMID>
  </reference>
  <reference>
    <citation>Mahabier KC, Den Hartog D, Theyskens N, Verhofstad MHJ, Van Lieshout EMM; HUMMER Trial Investigators. Reliability, validity, responsiveness, and minimal important change of the Disabilities of the Arm, Shoulder and Hand and Constant-Murley scores in patients with a humeral shaft fracture. J Shoulder Elbow Surg. 2017 Jan;26(1):e1-e12. doi: 10.1016/j.jse.2016.07.072. Epub 2016 Oct 10.</citation>
    <PMID>27745806</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Humeral shaft fracture</keyword>
  <keyword>Diaphysis</keyword>
  <keyword>Fracture fixation</keyword>
  <keyword>Fracture Healing</keyword>
  <keyword>Aged</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Comparative study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

